SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Vor Biopharma Reports Third-Quarter 2026 Net Loss of $86.7 Million

Vor Biopharma reported a third-quarter net loss of $86.7 million, compared with a loss of $812.7 million a year earlier. Loss per share narrowed to $1.45 from $121.63, primarily reflecting a $757.6 million decrease in warrant-liability fair-value expense. The company reported no revenue.

VOR

Related stories